



IFW

**TRANSMITTAL LETTER
(General - Patent Pending)**Docket No.
01200/1/USIn Re Application Of: **Danchen Gao et al.**Serial No.
10/741,530Filing Date
December 18, 2003Examiner
UnknownGroup Art Unit
1616**Title: ACCEPTABLY NON-HYGROSCOPIC FORMULATION INTERMEDIATE COMPRISING A
HYGROSCOPIC DRUG****TO THE COMMISSIONER FOR PATENTS:**

Transmitted herewith is:

Information Disclosure Statement; Form 1449; Cited References (6); Itemized Postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1025** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.



Signature

Dated: July 19, 2004

**Patricia K. Fitzsimmons, Reg. No. 52,894
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.1490**

I certify that this document and fee is being deposited
July 19, 2004 with the U.S. Postal Service as
first class mail under 37 C.F.R. 1.8 and is addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.



Signature of Person Mailing Correspondence**Linda K. Cooper**

Typed or Printed Name of Person Mailing Correspondence

cc:



PATENT
Case 01200/1/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Danchen Gao et al.) GROUP ART UNIT: 1616
SERIAL NO.: 10/741,530) CONFIRMATION NO.: 4628
EXAMINER: Unknown) ATTORNEY DOCKET
FILED: December 18, 2003) NO.: 01200/1/US
TITLE: ACCEPTABLY NON-HYGROSCOPIC FORMULATION INTERMEDIATE
COMPRISING A HYGROSCOPIC DRUG

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97 and 1.98

July 19, 2004

Commissioner of Patents
Box 1450
Alexandria, VA 22313

Sir:

This Information Disclosure Statement is filed pursuant to 37 CFR 1.97 and 1.98 and
* MPEP §609. Copies of the references listed on the attached Form PTO-1449 are enclosed herein.

Each item contained in this Information Disclosure Statement was first cited in a
communication from a foreign patent office in a counterpart foreign application not more than
three months prior to the filing of this Information Disclosure Statement. No fee is required
under §1.97.

Please charge any fee required by §1.97 to Deposit Account No. 19-1025.

Respectfully submitted,

Patricia K. Fitzsimmons
Patricia K. Fitzsimmons
Attorney for Applicants
Registration No. 52,894
(314) 274-1490

Pharmacia Corporation
of Pfizer Inc.
Global Patent Department
Post Office Box 1027
St. Louis, MO 63006

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

01200/1/US

Application Number

10/741,530

Applicant(s)

Danchen Gao et al.

Filing Date

December 18, 2003

Group Art Unit

1616

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	4,835,187	05/30/1989	Reuter et al.	514/570		06/15/1987
	2.	5,582,837	12/10/1996	Shell	424/451		05/30/1995
	3.	5,939,100	08/17/1999	Albrechtsen et al.	424/489		10/03/1994
	4.	Pub. No.US2002/0143058	10/03/2002	Safadi et al.	514/557		01/24/2001

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	5.	WO 01/72703	10/04/2001	PCT	323/58		✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	6.	PCT Search Report, 4 pgs.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.